Livingston G K, Foster A E, Elson H R
Department of Environmental Health, University of Cincinnati College of Medicine, Ohio.
J Toxicol Environ Health. 1993 Oct-Nov;40(2-3):367-75. doi: 10.1080/15287399309531802.
The validity of the micronucleus test as a biomarker of chromosome damage in dividing mammalian cells is well established. This assay was used to study the response of peripheral lymphocytes of a 34-yr-old male patient following treatment with 131I ablative radiation therapy following a total thyroidectomy. Coincidentally, 8 mo before diagnosis, the patient had provided a blood sample for an in vitro study of micronucleus induction following exposure to graded doses of x-rays. The background frequency in the unexposed culture showed a mean count of 6.0 micronuclei per 1000 binucleated (first division) lymphocytes, while mean values of 18.5, 29.0, 41.0, 61.0 and 75.5 micronuclei/1000 cells were observed following x-ray doses of 5, 10, 15, 20, and 25 cGy, respectively. These data fit a nonthreshold, linear dose-response function (y = 2.78x + 3.71; r = .99). Eight months after the in vitro x-ray study, the subject was diagnosed with thyroid cancer. Surgery was performed, and 5 wk later the patient received 1.78 GBq (48 mCi) of 131I as adjuvant radiation therapy. Blood was drawn 11 d after the radiation treatment and at monthly intervals thereafter to analyze the frequency and persistence of micronuclei. The first posttreatment sample showed 35.5 micronuclei per 1000 binucleate cells. Based on the linear dose-response equation from the earlier study, the sixfold increase in micronucleus frequency suggests a dose to the peripheral blood of approximately 11 cGy. The cytogenetic dose estimate compares to approximately 30 cGy using a new model based on external whole-body counting data. Nine consecutive monthly samples have been analyzed to date. Although the micronucleus count has fluctuated (four- to sixfold above background), the frequency after 8 mo is equivalent to the first posttreatment sample. Data show that radiation-induced cellular lesions persist for months following relatively brief radiation exposure to a medical isotope. Results of this study support the conclusion that the lymphocyte micronucleus test is a rapid, sensitive, and perhaps quantitative biomarker of low-dose (< 25 cGy) radiation exposure.
微核试验作为分裂哺乳动物细胞中染色体损伤生物标志物的有效性已得到充分证实。该试验用于研究一名34岁男性患者在全甲状腺切除术后接受131I消融放射治疗后外周淋巴细胞的反应。巧合的是,在诊断前8个月,该患者曾提供一份血液样本用于体外研究分级剂量X射线照射后微核的诱导情况。未照射培养物中的背景频率显示,每1000个双核(第一次分裂)淋巴细胞中微核的平均计数为6.0个,而在5、10、15、20和25 cGy的X射线剂量照射后,观察到的微核平均数值分别为每1000个细胞18.5、29.0、41.0、61.0和75.5个。这些数据符合非阈值线性剂量反应函数(y = 2.78x + 3.71;r = 0.99)。体外X射线研究8个月后,该受试者被诊断为甲状腺癌。进行了手术,5周后患者接受了1.78 GBq(48 mCi)的131I作为辅助放射治疗。在放射治疗后11天及此后每月采集血液样本,以分析微核的频率和持续性。治疗后的第一个样本显示,每1000个双核细胞中有35.5个微核。根据早期研究的线性剂量反应方程,微核频率增加六倍表明外周血的剂量约为11 cGy。使用基于外部全身计数数据的新模型,细胞遗传学剂量估计约为30 cGy。迄今为止,已对连续9个每月样本进行了分析。尽管微核计数有波动(比背景高四到六倍),但8个月后的频率与治疗后的第一个样本相当。数据表明,在相对短暂地暴露于医用同位素辐射后,辐射诱导的细胞损伤会持续数月。本研究结果支持以下结论:淋巴细胞微核试验是低剂量(<25 cGy)辐射暴露的快速、敏感且可能定量的生物标志物。